MicroRNA ‐326 negatively regulates CD155 expression in lung adenocarcinoma
Cancer Science · 2023
DOI: 10.1111/cas.15921 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, 2023. Verfasst von Takayuki Nakanishi und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, MicroRNAs, Adenocarcinoma of Lung. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Treatment with immune checkpoint inhibitors induces a durable response in some patients with non‐small‐cell lung cancer, but eventually gives rise to drug resistance. Upregulation of CD155 expression is implicated as one mechanism of resistance to programmed death receptor‐1 (PD‐1)/PD‐1 ligand (PD‐L1) inhibitors, and it is therefore important to characterize the mechanisms underlying regulation of CD155 expression in tumor cells. The aim of this study was to identify microRNAs (miRNAs) that might regulate CD155 expression at the posttranscriptional level in lung cancer. Comprehensive miRNA screening with target prediction programs and a dual‐luciferase reporter assay identified miR‐346, miR‐328‐3p, miR‐326, and miR‐330‐5p as miRNAs that bind to the 3′‐UTR of CD155 mRNA. Forced expression of these miRNAs suppressed CD155 expression in lung cancer cell lines. Immunohistochemical staining of CD155 in tissue specimens from 57 patients with lung adenocarcinoma revealed the median tumor proportion score for CD155 to be 68%. The abundance of miR‐326 in these specimens with a low level of CD155 expression was significantly greater than in specimens with a high level ( p < 0.005). Our results thus suggest that miR‐326 negatively regulates CD155 expression in lung adenocarcinoma and might therefore play a role in the development of resistance to PD‐1/PD‐L1 inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
- Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
- Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
ORCID-Profile: Yasuto Yoneshima, Eiji Iwama, Yoshinao Oda
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Nakanishi, T., Yoneshima, Y., Okamura, K., Yanagihara, T., Hashisako, M., Iwasaki, T., Haratake, N., Mizusaki, S., Ota, K., Iwama, E., Takenaka, T., Tanaka, K., Yoshizumi, T., Oda, Y., & Okamoto, I. (2023). MicroRNA ‐326 negatively regulates CD155 expression in lung adenocarcinoma. Cancer Science. https://doi.org/10.1111/cas.15921
Vancouver
Nakanishi T, Yoneshima Y, Okamura K, Yanagihara T, Hashisako M, Iwasaki T, et al. MicroRNA ‐326 negatively regulates CD155 expression in lung adenocarcinoma. Cancer Science. 2023. doi:10.1111/cas.15921
BibTeX
@article{Nakanishi2023,
author = {Nakanishi, Takayuki and Yoneshima, Yasuto and Okamura, Koji and Yanagihara, Toyoshi and Hashisako, Mikiko and Iwasaki, Takeshi and Haratake, Naoki and Mizusaki, Shun and Ota, Keiichi and Iwama, Eiji and Takenaka, Tomoyoshi and Tanaka, Kentaro and Yoshizumi, Tomoharu and Oda, Yoshinao and Okamoto, Isamu},
title = {MicroRNA ‐326 negatively regulates CD155 expression in lung adenocarcinoma},
journal = {Cancer Science},
year = {2023},
doi = {10.1111/cas.15921}
}
EUVIMED